[1]张 林,白 俐.扶正化瘀胶囊对慢性阻塞性肺疾病患者炎性因子及 MMP-9、TIMP-1的影响[J].医学信息,2018,31(14):152-155.[doi:10.3969/j.issn.1006-1959.2018.14.047]
　ZHANG Lin,BAI Li.Effect of Fuzheng Huayu Capsule on Inflammatory Factors,MMP-9 and TIMP-1 in Patients with Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2018,31(14):152-155.[doi:10.3969/j.issn.1006-1959.2018.14.047]
点击复制

扶正化瘀胶囊对慢性阻塞性肺疾病患者炎性因子及 MMP-9、TIMP-1的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
31卷
期数:
2018年14期
页码:
152-155
栏目:
中医中药
出版日期:
2018-07-15

文章信息/Info

Title:
Effect of Fuzheng Huayu Capsule on Inflammatory Factors,MMP-9 and TIMP-1 in Patients with Chronic Obstructive Pulmonary Disease
文章编号:
1006-1959（2018）14-0152-04
作者:
张 林; 白 俐
广东药科大学附属第二医院/广州新海医院重症医学科，广东 广州 510300
Author(s):
ZHANG Lin; BAI Li
The Second Affiliated Hospital of Guangdong Pharmaceutical University/Department of Critical Care Medicine,Guangzhou Xinhai Hospital,Guangzhou 510300,Guangdong,China
关键词:
慢性阻塞性肺疾病; 扶正化瘀胶囊; 白细胞介素-6; 肿瘤坏死因子-α; 基质金属蛋白酶-9; 基质金属蛋白酶抑制剂-1
Keywords:
Key words：Chronic obstructive pulmonary disease; Fuzheng Huayu Capsule; Interleukin-6; Tumor necrosis factor-α; Matrix metalloproteinase-9; Matrix metalloproteinase inhibitor-1
分类号:
R259
DOI:
10.3969/j.issn.1006-1959.2018.14.047
文献标志码:
A
摘要:
目的 探讨扶正化瘀胶囊对稳定期中重度慢性阻塞性肺疾病患者肺功能影响及其可能机制。方法 选取我院136例稳定期中重度慢性阻塞性肺疾病患者，随机分为对照组和实验组，每组68例。对照组予常规治疗，实验组在对照组基础上加用扶正化瘀胶囊，持续8周。比较两组患者治疗前后肺功能（FEV1%、FEV1/FCV）、血清中炎症因子（IL-6、TNF-α）及MMP-9、TIMP-1浓度。结果 治疗后，实验组FEV1%、FEV1/FCV分别为（58.17±6.89）%和（63.57±7.11），高于对照组的（51.67±5.32）%和（57.87±9.18），差异具有统计学意义（P＜0.05）；实验组IL-6、TNF-α分别为（3.24±1.69）pg/ml和（2.41±0.53）pg/ml，低于对照组的（3.63±1.72）pg/ml和（2.77±0.62）pg/ml，差异具有统计学意义（P＜0.05）；实验组MMP-9、TIMP-11分别为（122.16±16.37）ng/ml、（10.32±21.77）ng/ml，低于对照组的（186.32±15.36）ng/ml、（140.13±19.68）ng/ml，差异具有统计学意义（P＜0.05）。治疗后实验组MMP-9/TIMP-1比值为（1.11±0.21），较对照组的（1.31±0.27）更趋于平衡，差异有统计学意义（P＜0.05）。结论 扶正化瘀胶囊能改善稳定期慢性阻塞性肺疾病患者肺功能情况，其机制与降低炎症反应及胞外基质沉积相关。
Abstract:
Abstract：Objective To investigate the effect of Fuzheng Huayu Capsule on pulmonary function in patients with moderate to severe chronic obstructive pulmonary disease at stable stage and its possible mechanism.Methods A total of 136 patients with stable moderate to severe chronic obstructive pulmonary disease were randomly divided into control group and experimental group,with 68 cases in each group.The control group received routine treatment,and the experimental group was given Fuzheng Huayu Capsule on the basis of the control group for 8 weeks.The lung function (FEV1%,FEV1/FCV),serum inflammatory factors (IL-6,TNF-α),MMP-9 and TIMP-1 concentrations were compared before and after treatment.Results After treatment,the FEV1% and FEV1/FCV of the experimental group were(58.17±6.89)% and(63.57±7.11),respectively,which were higher than those of the control group(51.67±5.32)% and(57.87±9.18),the difference was statistically significant(P<0.05);IL-6 and TNF-α in the experimental group were(3.24±1.69)pg/ml and(2.41±0.53)pg/ml,respectively,which was lower than that of the control group(3.63±1.72)pg/ml and(2.77±0.62)pg/ml,the difference was statistically significant(P<0.05);The MMP-9 and TIMP-11 in the experimental group were(122.16±16.37)ng/ml and(10.32±21.77) ng/ml,respectively,which was lower than that of the control group(186.32±15.36)ng/ml,(140.13±19.68)ng/ml,the difference was statistically significant(P<0.05).After treatment,the MMP-9/TIMP-1 ratio in the experimental group was(1.11±0.21),which was more balanced than the control group(1.31±0.27),and the difference was statistically significant(P<0.05).Conclusion Fuzheng Huayu Capsule can improve the lung function of patients with stable chronic obstructive pulmonary disease,and its mechanism is related to the reduction of inflammatory reaction and extracellular matrix deposition.

参考文献/References:

[1]中华医学会呼吸病学会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南(2013年修订版)[J].中华结核和呼吸杂志,2013,36(4):255-264. [2]郑筱萸.中药新药临床研究指导原则[M].北京:中国医药科技出版社,2002:56-58. [3]赵长青,徐列明.扶正化瘀胶囊/片治疗肝纤维化和肝硬化的临床研究进展[J].世界中医药,2014,9(5):561-566. [4]陈晗,杨碧伟,袁满,等.扶正化瘀胶囊对肝纤维化大鼠的防治作用及对结缔组织生长因子表达的影响[J].四川大学学报(医学版),2016,47(2):197-202. [5]祁轶斐,任学娇,娄利霞,等.扶正化瘀胶囊对心肌梗死后心肌纤维化大鼠细胞外基质代谢的影响[J].中医杂志,2018,59(7):607-611. [6]张炜,毕小利,包蓓倩,等.扶正化瘀胶囊治疗慢性阻塞性肺疾病的临床研究[J].辽宁中医杂志,2008,36(8):1174-1175. [7]Tse HN,Tseng CZ.Update on the pathological processes,molecularbiologyand clinical utility of N-acetylcysteine in chronic obstructive pulmonary disease[J].Int J Chron Obstruct Pulmon Dis,2014(9):825-836. [8]潘阳新,陈人生,李艳丽,等.他汀类药物对慢性阻塞性肺疾病患者气道炎症的影响[J].慢性病学杂志,2017,18(2):188-189,192. [9]Garvin P,Nilsson E,Ernerudh J,et al.The joint subclinical elevation of CRP and IL-6 is associated with lower health related quality of life in comparison with no elevation or elevation of only one of the biomarkers[J].Qual Life Res,2016,25(1):213-221. [10]杨柳,谢丽华,孙圣华.慢性阻塞性肺疾病全身炎症表型的特点[J].国际呼吸杂志,2014,34(5):390-394. [11]吕华亮,李洪涛,张天托,等.吸烟对轻度COPD患者血清中氧化应激及炎症因子的影响[J].中华肺部疾病杂志(电子版),2017,10(6):681-685. [12]孙杰,韩敏娟.咳喘宁胶囊对慢性阻塞性肺疾病稳定期患者气道炎症细胞及炎性介质的影响[J].中国中医药信息杂志,2014,21(9):21-23. [13]易辉,王树立,崔江禹.COPD患者C反应蛋白、TNF-α、IL-8、IL-6临床研究[J].现代生物医学进展,2011,11(3):534-537. [14]任静.血清中IL-6、TNF-a与慢性阻塞性肺疾病患者病情分级、呼吸功能的关系[J].囯际检验医学杂志,2017,38(13):1781-1783. [15]Higashimoto Y,Yamagata Y,Iwata T,et al.Increased serum concentrations of tissue inhibitor of metalloproteinase-1 in COPD patients[J].Eur Respir J,2005,25(5):885-890. [16]Ko FW,Diba C,Roth M,et al.A comparison of airway and serum malrlxmetalloproteinase-9 activity among normal subjects,asthmatic patients,and patients with asthmatic mucus hypersecretion[J].Chest,2005,127(6):1919-1927. [17]赵雪峰,王红阳,杨万杰.COPD患者血细胞因子水平与肺功能的相关性分析[J].安徽医学,2010,31(6):559-562. [18]郝艳萍.慢阻肺患者血清中MMP-9、TIMP-1及ICAM-1的相关作用研究[J].临床肺科杂志,2013,18(3):500-501. [19]辛晓峰,赵明,李子玲,等.支气管哮喘和慢性阻塞性肺疾病患者诱导痰中基质金属蛋白酶及其抑制剂与气道炎症及气流受限[J].中华结核和呼吸杂志,2007,30(3):192-196. [20]高蔚,翁婷.慢性阻塞性肺疾病患者血清及痰中基质金属蛋白酶-9、转化生长因子-13水平及意义[J].实用医学杂志,2011,27(18):3355-3357.

相似文献/References:

[1]钟雪梅,李 黎,米热班·热夏提,等.α1-抗胰蛋白酶与维吾尔族慢性阻塞性肺疾病的相关性分析[J].医学信息,2018,31(02):67.[doi:10.3969/j.issn.1006-1959.2018.02.023]
　ZHONG Xue-mei,LI Li,Mirban·rixat,et al.Correlation Analysis of α1-antitrypsin and Uygur Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2018,31(14):67.[doi:10.3969/j.issn.1006-1959.2018.02.023]
[2]陈文福.噻托溴铵治疗稳定期慢性阻塞性肺疾病的临床疗效分析[J].医学信息,2018,31(02):124.[doi:10.3969/j.issn.1006-1959.2018.02.045]
　CHEN Wen-fu.Clinical Analysis of Tiotropium Bromide in the Treatment of Stable Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2018,31(14):124.[doi:10.3969/j.issn.1006-1959.2018.02.045]
[3]吴仲东.无创机械通气用于COPD合并呼吸衰竭的疗效分析[J].医学信息,2018,31(04):106.[doi:10.3969/j.issn.1006-1959.2018.04.036]
　WU Zhong-dong.Clinical Analysis of Noninvasive Mechanical Ventilation in Patients with COPD Complicated with Respiratory Failure[J].Journal of Medical Information,2018,31(14):106.[doi:10.3969/j.issn.1006-1959.2018.04.036]
[4]龙有珠.氨茶碱联合呼吸功能训练治疗慢性阻塞性肺疾病的疗效分析[J].医学信息,2018,31(04):127.[doi:10.3969/j.issn.1006-1959.2018.04.045]
　LONG You-zhu.Effect of Aminophylline Combined with Respiratory Function Training on Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2018,31(14):127.[doi:10.3969/j.issn.1006-1959.2018.04.045]
[5]皮鑫鑫,邓 革.临床药师对1例院内感染患者的病例分析[J].医学信息,2018,31(04):188.[doi:10.3969/j.issn.1006-1959.2018.04.072]
[6]罗 倩.COPD加重期患者肺功能、血气指标及 炎症指标的变化分析[J].医学信息,2018,31(09):114.[doi:10.3969/j.issn.1006-1959.2018.09.034]
　LUO Qian.Changes of Pulmonary Function,Blood Gas and Inflammation in Patients with COPD Exacerbation[J].Journal of Medical Information,2018,31(14):114.[doi:10.3969/j.issn.1006-1959.2018.09.034]
[7]赵志国.有创-无创序贯通气疗法治疗慢性阻塞性肺疾病 引发的严重呼吸衰竭的临床研究[J].医学信息,2018,31(11):110.[doi:10.3969/j.issn.1006-1959.2018.11.034]
　ZHAO Zhi-guo.Clinical Study of Invasive Non-invasive Sequential Ventilation in Treatment of Severe Respiratory Failure Caused by Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2018,31(14):110.[doi:10.3969/j.issn.1006-1959.2018.11.034]
[8]金彦青.NPPV治疗慢性阻塞性肺疾病合并 重症呼吸衰竭的临床疗效观察[J].医学信息,2018,31(14):113.[doi:10.3969/j.issn.1006-1959.2018.14.033]
　JIN Yan-qing.Clinical Efficacy of NPPV in the Treatment of Chronic Obstructive Pulmonary Disease with Severe Respiratory Failure[J].Journal of Medical Information,2018,31(14):113.[doi:10.3969/j.issn.1006-1959.2018.14.033]
[9]何冬兰,李 文.NLR、PLR在慢性阻塞性肺疾病进展、预后中的相关研究[J].医学信息,2022,35(11):25.[doi:10.3969/j.issn.1006-1959.2022.11.008]
　HE Dong-lan,LI Wen.Study on Correlation Between NLR and PLR in the Progression and Prognosis of Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2022,35(14):25.[doi:10.3969/j.issn.1006-1959.2022.11.008]
[10]张善芳,汤 杰.穴位注射联合沙美特罗替卡松粉吸入剂治疗 慢性阻塞性肺疾病稳定期的临床疗效观察[J].医学信息,2018,31(16):131.[doi:10.3969/j.issn.1006-1959.2018.16.041]
　ZHANG Shan-fang,TANG Jie.Clinical Observation of Acupoint Injection Combined with Salmeterol and Fluticasone Powder Inhalation in the Treatment of Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2018,31(14):131.[doi:10.3969/j.issn.1006-1959.2018.16.041]

更新日期/Last Update: 2018-07-15